The Human Upgrade with Dave Asprey

Can Injectable MDMA Become the Next Biohack in 2026? RFK Jr. vs FDA – Rick Doblin : 1290

22 snips
Jun 12, 2025
Rick Doblin, founder of MAPS and an authority in psychedelic research, delves into the revolutionary potential of MDMA-assisted therapy for mental health. He discusses the FDA's regulatory battles and the juxtaposition of pharmaceutical profits against public benefit. The conversation emphasizes the transformative power of psychedelics in emotional resilience and neuroplasticity. With a focus on structured therapy settings, Doblin highlights innovative applications, including couples therapy, and urges a paradigm shift in the approach to psychedelics and trauma healing.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

MDMA Only Works With Therapy

  • Psychedelic drugs like MDMA have great medical potential with minimal harms when used properly.
  • Separating psychedelics from therapy to focus just on the drug is a dangerous and ineffective approach.
INSIGHT

MDMA Therapy Shift to Pharma

  • MDMA therapy advanced through nonprofit efforts but shifted towards a for-profit pharmaceutical model, reducing public benefit focus.
  • This change led to prioritizing shareholder returns over patient benefits and separating therapy from the drug.
ADVICE

Enhance Therapy With Neurofeedback

  • Combine psychedelic medicines with neurofeedback or therapy to enhance brain changes and deepen healing.
  • Use integrative tools to accelerate accessing therapeutic states without being overly 'high' or dependent on altered states.
Get the Snipd Podcast app to discover more snips from this episode
Get the app